Samumed Company

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Technology: Other
Industry: P4 Medicine
Headquarters: United States
Founded Date: 2008-01-01
Employees Number: 51-100
Investors Number: 5
Total Funding: $658M
Estimated Revenue: $10M to $50M
Last Funding Type: Series C

Visit Website
info@samumed.com
https://www.twitter.com/samumed_llc
Register and Claim Ownership